OHSU Knight Cancer Institute
This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as mosunetuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as etoposide, doxorubicin, vincristine, cyclophosphamide and prednisone work in different ways to stop the growth of cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mosunetuzumab with chemotherapy may be safe, tolerable and/or effective in treating patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma.
PRIMARY OBJECTIVES: I. Evaluate the safety and tolerability of the mosunetuzumab (M) plus dose-adjusted (DA) etoposide, doxorubicin, vincristine, cyclophosphamide, and prednisone \[EPOCH\] combination in previously untreated c-Myc + diffuse large B cell lymphoma (DLBCL) and high-grade B cell lymphoma. (Phase Ib) II. Evaluate the efficacy of M DA EPOCH as complete response (CR) in previously untreated c-Myc + DLBCL and high grade B cell lymphoma. (Phase II) SECONDARY OBJECTIVES: I. Evaluate the efficacy of M DA EPOCH in Phase Ib and II as overall response, durability of response, and surviva…
Inclusion Criteria: * For both phases of the study, participant must be 18-75 years of age and have previously untreated high-grade B cell lymphoma (HGBCL) or diffuse large B cell lymphoma (DLBCL), including transformed DLBCL per the World Health Organization (WHO) 2022 classification, and with documented c-Myc rearrangement on fluorescence in situ hybridization (FISH) testing. Eligible types of c-Myc rearrangements will be performed by FISH testing and may include any single MYC rearrangement (single-hit lymphoma \[SHL\]), Double hit (DHL) lymphoma or and triple hit (THL) lymphoma defined by…
Undergo tumor biopsy
Undergo blood sample collection
Undergo bone marrow aspiration and biopsy
Undergo CT scan
Given IV
Given IV
Undergo echocardiography
Given IV
Undergo MRI
Given IV
Undergo MUGA
Undergo PET scan
Given PO
Given IV